Cyclosporine a Nephrotoxicity

  • V. E. Andreucci
  • G. Fuiano
Part of the International Yearbooks of Nephrology book series (IYNE, volume 1)


Despite the many studies performed both in humans and in experimental animals during the decade which has elapsed since the introduction of Cyclosporine A (CyA) into clinical practice, the mechanisms by which CyA damages the kidneys is still poorly defined. The main problem faced in the past years in studying CyA nephrotoxicity is related to the almost exclusive clinical use of CyA in renal transplant recipients, i.e. in patients who initially (soon after transplantation) exhibit, in the transplanted kidney, the consequences of ischemic injury, and then undergo acute and/or chronic renal allograft rejection; these conditions make CyA-induced renal impairment difficult to isolate. Only in recent years has clinical experience been gained in humans with previously healthy native kidneys, i.e. in heart, liver or bone marrow transplant recipients or in patients treated with CyA for extrarenal diseases (1).


Plasma Renin Activity Renal Blood Flow Renal Transplant Recipient Renal Allograft Renal Transplant Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Andreucci VE, Conte G, Sabbatini M, Fuiano G, De Nicola L, Stanziale P, Sepe V, Balletta M: Cyclosporine nephrotoxicity. Proc. 2nd Int. Sorrento Meeting on “Current Therapy in Nephrology”, Sorrento, May 22–25, 1988, (Eds. VE Andreucci and A. Dal Canton), Kluwer Academic Publ, Boston, 1988.Google Scholar
  2. 2.
    Makowka L, Lopatin W, Gilas T, Falk J, Phillips MJ, Falk R: Prevention of cyclosporine (CyA) nephrotoxicity by synthetic prostaglandins. Clin Nephrol, 25 (Suppl 1): S89–S94, 1986.PubMedGoogle Scholar
  3. 3.
    Pfaller W, Kotanko P, Bazzanella A: Morphological and biochemical observations in rat nephron epithelia following cyclosporine A treatment. Clin Nephrol, 25 (Suppl 1): S105–S110, 1986.PubMedGoogle Scholar
  4. 4.
    Suzuki S, Oka T, Ohkuma S, Kuriyarna K: Biochemical mechanisms underlying cyclosporine-induced nephrotoxicity: effect of concomitant administration of prednisolone. Transplantation, 44: 363–368, 1987.PubMedCrossRefGoogle Scholar
  5. 5.
    Nagineni CN, Misra BC, Lee DBN, Yanagawa N: Cyclosporine A-calcium channel interaction: a possible mechanism for nephrotoxicity. Transplant Proc, 19: 1358–1362, 1987.PubMedGoogle Scholar
  6. 6.
    McMillen MA, Baumgarten WKm Schaefer HC, Mitchnick E, Fuortes M, Holman MJ, Tesi RJ: The effect of verapamil on cellular uptake, organ distribution, and pharmacology of cyclosporine. Transplantation, 44: 395–401, 1987.PubMedCrossRefGoogle Scholar
  7. 7.
    Brown Z, Neild GH, Willoughby JJ, Somia NV, Cameron SJ: Increased factor VIII as an index of vascular injury in cyclosporine nephrotoxicity. Transplantation, 42: 150–153, 1986.PubMedCrossRefGoogle Scholar
  8. 8.
    McNaughton DC, White DJG: The differential diagnosis of rejection and nephrotoxicity in renal allograft recipients treated with cyclosporin A. Med Sci Res, 15: 307–308, 1987.Google Scholar
  9. 9.
    D’Ardenne AJ, Dunnill MS, Thompson JF, McWhinnie D, Wood RFM, Morris PJ: Cyclosporin and renal graft histology. J Clin Pathol, 39: 145–151, 1986.PubMedCrossRefGoogle Scholar
  10. 10.
    Chapman JR, Griffiths D, Harding NGL, Morris PJ: Reversibility of cyclosporin nephrotoxicity after three months treatment. Lancet, 1: 128–129, 1985.PubMedCrossRefGoogle Scholar
  11. 11.
    Palestine AG, Austin HA III, Nussenblatt RB: Renal tubular function in cyclosporine-treated patients. Am J Med, 81: 419–424, 1986.PubMedCrossRefGoogle Scholar
  12. 12.
    Humes HD, Jackson NM, O’Connor RP, Hunt DA, White MD: Pathogenetic mechanisms of nephrotoxicity: insights into cyclosporine nephrotoxicity. Transplant Proc, 19: 51–62, 1985.Google Scholar
  13. 13.
    Dieperink H, Leyssac PP, Starklint H, Kemp E: Nephrotoxicity of cyclosporin A. A lithium clearance and micropuncture study in rats, Eur J Clin Invest, 16: 69–77, 1986.PubMedCrossRefGoogle Scholar
  14. 14.
    Dieperink H, Leyssac PP, Starklint H, Jorgensen KA, Kemp E: Antagonist capacities of nifedipine, Captopril, phenoxybenzamine, prostacyclin and indomethacin on cyclosporin A induced impairment of rat renal function. Eur J Clin Invest, 16: 540–548, 1986.PubMedCrossRefGoogle Scholar
  15. 15.
    Andreucci VE: Acute Renal Failure. Pathophysiology, prevention, and treatment. Martinus Nijhoff Publ, Boston, 1984Google Scholar
  16. 16.
    Verpooten GA, Wybo I, Pattyn VM, Hendrix PG, Giuliano RA, Nouwen EJ, Roels F, De Broe ME: Cyclosporine nephrotoxicity: comparative cytochemical study of rat kidney and human allograft biopsies. Clin Nephrol, 25 (Suppl 1): S18-S22, 1986.PubMedGoogle Scholar
  17. 17.
    English J, Evan A, Houghton DC, Bennett WM: Cyclosporine-induced acute renal dysfunction in the rat. Transplantation, 44: 135–141, 1987.PubMedCrossRefGoogle Scholar
  18. 18.
    Whiting PH, Simpson JG: Lithium clearance measurements as an indication of cyclosporine A nephrotoxicity. Clin Sci, 74: 173–178, 1988.PubMedGoogle Scholar
  19. 19.
    Whiting PH, Thomson AW, Simpson JG: Cyclosporine and renal enzyme excretion. Clin Nephrol, 25 (Suppl 1): S100–S104, 1986.PubMedGoogle Scholar
  20. 20.
    Devineni R, McKenzie N, Duplan J, Keown P, Stiller C., Wallace AC: Renal effects of cyclosporine: clinical and experimental observations. Tranplant Proc, 15: (Suppl 1): 2695–2699, 1983.Google Scholar
  21. 21.
    Murray BM, Paller MS, Ferris TF: Effect of cyclosporine administration on renal hemodynamics in conscious rats. Kidney Int, 28: 767–774, 1985.PubMedCrossRefGoogle Scholar
  22. 22.
    Dieperink H, Leyssac PP, Kemp E, Steinbruckl D, Starklint H: Glomerulotubular function in cyclosporine A treated rats. Clin Nephrol, 25 (Suppl 1): S70-S74, 1986.PubMedGoogle Scholar
  23. 23.
    Sabbatini M, Esposito C., Uccello F, De Nicola L, Alba MM, Conte G, Dal Canton A, Andreucci VE: Acute effects of cyclosporine A on glomerular dynamics. Micropuncture study in the rat. Transplant Proc, 20 (N 3, Suppl 3), 1988.Google Scholar
  24. 24.
    Barros EJG, Boim MA, Ajzen H, Ramos OL, Schor N: Glomerular hemodynamics and hormonal participation on cyclosporine nephrotoxicity. Kidney Int, 32: 19–25, 1987.PubMedCrossRefGoogle Scholar
  25. 25.
    Sabbatini M, Esposito C., De Nicola L, Uccello F, Altomonte M, Romano G, Veniero P, Dal Canton A, Andreucci VE: Dopamine reverses acute cyclosporine A nephrotoxicity. Micropuncture study in the rat. Proc. 2nd Int Sorrento Meeting on “Current Therapy in Nephrology”, Sorrento May 22–25, 1988, (Eds. VE Andreucci and A. Dal Canton), Kluwer Academic Publ, Boston, 1988.Google Scholar
  26. 26.
    Schurek HJ, Neumann KH, Jesinghaus WP, Aeikens B, Wonigeit K: Influence of cyclosporine A on adaptive hypertrophy after unilateral nephrectomy in the rat. Clin Nephrol, 25 (Suppl 1): S144-S147, 1986.PubMedGoogle Scholar
  27. 27.
    Kaskel FJ, Devarajan P, Arbeit LA, Partin JS, Moore LC: Cyclosporine nephrotoxicity: sodium excretion, autoregulation, and angiotensin II. Am J Physiol, 252: F733-F742, 1987.PubMedGoogle Scholar
  28. 28.
    Gnutzmann KH, Hering K, Gutsche H-U: Effect of cyclosporine on the diluting capacity of the rat kidney. Clin Nephrol, 25 (Suppl 1): S51-S56, 1986.PubMedGoogle Scholar
  29. 29.
    Muller-Suur R, Davis SD: Effect of cyclosporine A on renal electrolyte transport: whole kidney and Hen le loop study. Clin Nephrol, 25 (Suppl 1): S57-S61, 1986.PubMedGoogle Scholar
  30. 30.
    Murray BM, Palier MS: Beneficial effects of renal denervation and prazosin on GFR and renal blood flow after cyclosporine in rats. Clin Nephrol, 25 (Suppl 1): S37-S39, 1986.PubMedGoogle Scholar
  31. 31.
    Gazdar AF, Dammin GJ: Neural degeneration and regeneration in human renal transplants. N Eng J Med, 283: 222–224, 1970CrossRefGoogle Scholar
  32. 32.
    Kawaguchi A, Goldman MH, Shapiro R, Foegh ML, Ramwell PW, Lower RR: Increase in urinary thromboxane B2 in rats caused by cyclosporine. Transplantation, 40: 214–216, 1985.PubMedCrossRefGoogle Scholar
  33. 33.
    Duggin GG, Baxter C., Hall BM, Horvath JS, Tiller DJ: Influence of cyclosporine A on intrarenal control of GFR. Clin Nephrol, 25 (Suppl 1): S43-S45, 1986.PubMedGoogle Scholar
  34. 34.
    Perico N, Benigni A, Zoja C., Delaini F, Remuzzi G: Functional significance of exaggerated renal thromboxane A2 synthesis induced by cyclosporin A. Am J Physiol, 251: F581–F587, 1986.PubMedGoogle Scholar
  35. 35.
    Elzinga L, Kelley VE, Houghton DC, Bennett WM: Modification of experimental nephrotoxicity with fish oil as the vehicle for cyclosporine. Transplantation, 43: 271–273, 1987.PubMedCrossRefGoogle Scholar
  36. 36.
    Conte G, Sabbatini M, Napödano P, De Nicola L, Gigliotti G, Fuiano G, Testa A, Russo D, Esposito C., Libetta C., Dal Canton A, Andreucci VE: Dopamine counteracts the acute renal effects of cyclosporine in normal subjects. Transplant Proc, 20 (N 3, Suppl 3): 563–567, 1988.PubMedGoogle Scholar
  37. 37.
    Conte G, Sabbatini M, De Nicola L, Gigliotti G, Fuiano G, Testa A, Sepe V, Imperatore P, Dal Canton A, Andreucci VE: Reversibility of acute cyclosporine renal impairment by dopamine in healrhy subjects. Proc. 2nd Int. Sorrento Meeting on “Current Therapy in Nephrology”, Sorrento, May 22–25, 1988, (Eds. VE Andreucci and A. Dal Canton), Kluwer Academic Publ, Boston, 1988.Google Scholar
  38. 38.
    Papa A, Lotito MA, Rampino T, Campolo G, Pacchiano G, Imperatore P, Memoli B, Libetta C., Milone D, Fuiano G: “Renal functional reserve” of renal transplant patients. Proc. 2nd Int. Sorrento Meeting on “Current Therapy in Nephrology”, Sorrento, May 22–25, 1988, (Eds. VE Andreucci and A. Dal Canton), Kluwer Academic Publ, Boston, 1988.Google Scholar
  39. 39.
    Kho TL, Teule J, Leunissen KML, Heidendal GAK, Lijnen PJ, Amery AK, van Hooff JP: Nephrotoxic effect of cyclosporine-A can be reversed by dopamine. Transplant Proc, 19: 1749–1753, 1987.PubMedGoogle Scholar
  40. 40.
    Dieperink H, Leyssac PP, Kemp E, Starklint H, Frandsen NE, Tvede N, Moller J, Buchler Frederiksen P, Rossing N: Nephrotoxicity of cyclosporin A in humans: effects on glomerular filtration and tubular reabsoprtion rates. Eur J Clin Invest, 17: 493–496, 1987.PubMedCrossRefGoogle Scholar
  41. 41.
    Hay R, Tammi K, Ryffel B, Mihatsch MJ: Alterations in molecular structure of renal mitochondria associated with cyclosporine A treatment. Clin Nephrol, 25 (Suppl 1): S23–S26, 1986.PubMedGoogle Scholar
  42. 42.
    Fournier N, Ducet 6, Crevat A: Action of cyclosporine on mitochondrial Ca++ effluxes. J Bioenerg Biomembranes, 19: 297–303, 1987.CrossRefGoogle Scholar
  43. 43.
    Myers BD: Cyclosporine nephrotoxicity. Kidney Int, 30: 964–974, 1986.PubMedCrossRefGoogle Scholar
  44. 44.
    Kanzai G, Stowe N, Steinmuller D, Ho-Hsieh H, Novick A: Effect of cyclosporine upon the function of ischemically damaged kidneys in the rats. Transplantation, 41: 782–785, 1986.CrossRefGoogle Scholar
  45. 45.
    Coffman TM, Carr DR, Yarger WE, Klotman PE: Evidence that renal prostaglandin and thromboxane production is stimulated in chronic cyclosporine nephrotoxicity. Transplantation, 43: 282–285, 1987.PubMedCrossRefGoogle Scholar
  46. 46.
    Bia MJ, Tyler KA: Effect of cyclosporine on renal ischemic injury. Transplantation, 43: 800–804, 1987.PubMedGoogle Scholar
  47. 47.
    Jablonski P, Harrison C., Howden B, Rae D, Tavanlis G., Marshall Vc, Tange JD: Cyclosporine and the ischemic rat kidney. Transplantation, 41: 147–151, 1986.PubMedCrossRefGoogle Scholar
  48. 48.
    Provoost AP, Kaptein L, Van Aken M: Nephrotoxicity of cyclosporine A in rats with a diminished renal function. Clin Nephrol, 25 (Suppl 1): S162–S167, 1986.PubMedGoogle Scholar
  49. 49.
    Dieperink H, Kemp E, Leyssac PP, Starklint H, Wanscher M, Nielsen J, Jorgensen KA, Faber V, Flachs H: Ketoconazole and cyclosporine A: combined effects on rat renal function and on serum and tissue cyclosporine A concentration. Clin Nephrol, 25 (Suppl 1): S137-S143, 1986.PubMedGoogle Scholar
  50. 50.
    Gonwa TA, Nghiem DD, Schulak JA, Corry RJ: Erythromycin and cyclosporine. Transplantation, 41: 797–799, 1986.PubMedCrossRefGoogle Scholar
  51. 51.
    Harnett JD, Parfrey PS, Paul MD, Gault MH: Erythromycin-cyclosporine interaction in renal transplant recipients. Transplantation, 43: 316–318, 1987.PubMedCrossRefGoogle Scholar
  52. 52.
    Jensen CWB, Flechner SM, Van Buren CT, Frazier OH, Cooley DA, Lorber MI, Kahan BD: Exhacerbation of cyclosporine toxicity by concomitant administration of erythromycin. Transplantation, 43: 263–270, 1987.PubMedCrossRefGoogle Scholar
  53. 53.
    Martell R, Heinrichs D, Stiller CR, Jenner M, Keown PA, Dupre J: The effects of erythromycin in patients treated with cyclosporine. Ann Intern Med, 104: 660–661, 1986.PubMedGoogle Scholar
  54. 54.
    Cantarovich M, Hiesse C., Lockiec F, Charpentier B, Fries D: Confirmation of the interaction between cyclosporine and the calcium channel blocker nicardipine in renal transplant patients. Clin Nephrol, 28: 190–193, 1987PubMedGoogle Scholar
  55. 55.
    Ryffel B, Muller AM, Mihatsch MJ: Experimental cyclosporine nephrotoxicity: risk of concomitant chemotherapy. Clin Nephrol, 25 (Suppl 1): S121-S125, 1986.PubMedGoogle Scholar
  56. 56.
    Brunner FP, Hermle M, Mihatsch MJ, Thiel G: Mannitol potentiates cyclosporine nephrotoxicity. Clin Nephrol, 25 (Suppl 1): S130-S136, 1986.PubMedGoogle Scholar
  57. 57.
    Cockburn ITR, Krupp P: Sandimmun. An appraisal of drug interactions. Proc. 2nd Int. Sorrento Meeting on “Current Therapy in Nephrology”, Sorrento, May 22–25, 1988, (Eds. VE Andreucci and A. Dal Canton), Kluwer Academic Publ, Boston, 1988.Google Scholar
  58. 58.
    Tindall RSA, Rollins JA, Phillips JT, Greenlee RG, Wells L, Belendiuk G: Preliminary results of a double-blind, randomized, placebo-onctrolled trial of cyclosporine in Myasthenia gravis. N Eng J Med, 316: 719–724, 1987.CrossRefGoogle Scholar
  59. 59.
    Fulano G, Stanziale P, Cianfrone P, Balletta M, Conte G, Libetta C., Guida B, Bisesti V, Sepe V: Effects of cyclosporine A on renal function and proteinuria in patients with nephrotic syndrome after a single oral administration. Proc. 2nd Int. Sorrento Meeting on “Current Therapy in Nephrology”, Sorrento, May 22–25, 1988, (Eds. VE Andreucci and A. Dal Canton), Kluwer Academic Publ, Boston, 1988.Google Scholar
  60. 60.
    Maiorca R, Cristinelli L, Scolari F, Sandrini S, Savoldi S, Brunori G, Prati E, Lojacono L, Salerni B, Tonini G: Cyclosporine toxicity can be minimized by careful monitoring of blood levels. Transpant Proc, 17 (Suppl 2): 54–59, 1985.Google Scholar
  61. 61.
    Holt DW, Marsden JT, Johnston A, Bewick M, Taube DH: Blood cyclosporin concentration and renal allograft dysfunction. Br Med J, 293: 1057–1058, 1986.CrossRefGoogle Scholar
  62. 62.
    Niebel W, Metz K, Donhuijsen D, Albrecht KH, Windeck R, Eigler FW: The effect of low-dose cyclosporine A on histopathologic findings in transplant biopsy specimens and function rates after cadaver renal transplantation. Transplant Proc, 19: 1772–1775, 1987.PubMedGoogle Scholar
  63. 63.
    Bennett WM, Norman DJ: Action and toxicity of cyclosporine. Annu Rev Med, 37: 215–224, 1986.PubMedCrossRefGoogle Scholar
  64. 64.
    Neild GH, Taube DH, Hartley RB, Bignardi L, Cameron JS, Williams DG, Ogg CS, Rudge CJ: Morphological differentiation between rejection and cyclosporin nephrotoxicity in renal allografts. J Clin Pathol, 39: 152–159, 1986.PubMedCrossRefGoogle Scholar
  65. 65.
    Mihatsch MJ, Ryffel B, Hermle M, Brunner FP, Thiel G: Morphology of cyclosporins nephrotoxicity in the rat. Clin Nephrol, 25 (Suppl 1): S2-S8, 1986.PubMedGoogle Scholar
  66. 66.
    Verani R: Cyclosporine nephrotoxicity in the Fisher rat. Clin Nephrol, 25 (Suppl 1): S9-S13, 1986.PubMedGoogle Scholar
  67. 67.
    Bertani T, Perico N, Abbate M, Battaglia C., Remuzzi G: Renal injury induced by long-term administration of cyclosporin A to rats. Am J Pathol, 127: 569–579, 1987.PubMedGoogle Scholar
  68. 68.
    von Willebrand E, Hayry P: Cyclosporin-A deposits in renal allografts. Lancet, 2: 189–192, 1983.CrossRefGoogle Scholar
  69. 69.
    Kolbeck PC, Wolfe JA, Burchette J, Sanfilippo F: Immunopathologic patterns of cyclosporine deposition associated with nephrotoxicity in renal allograft biopsies. Transplantation, 43: 218–224, 1987.PubMedCrossRefGoogle Scholar
  70. 70.
    Shen SY, Weir MR, Revie DR, Dagher FJ, Bentley FR, Chretien PB: Differentiation of acute rejection from acute cyclosporine nephrotoxicity in renal transplants by peripheral T cell subset counts. Transplant Proc, 19: 1776–1779, 1987.PubMedGoogle Scholar
  71. 71.
    Shulmann H, Striker G, Deeg HJ, Kennedy M, Storb R, Thomas ED: Nephrotoxicity of cyclosporine A after allogeneic marrow transplantation: glomerular thromboses and tubular injury. N Eng J Med, 305: 1392–1395, 1981.CrossRefGoogle Scholar
  72. 72.
    Atkinson K, Briggs JC, Hayes H, Ralston M, Dodds AJ, Concannon AJ, Naidoo D: Cyclosporin A-associated nephrotoxicity in the first days after allogeneic bone marrow transplantation: three distinct syndromes. Br J Hematol, 54: 59–67, 1983.CrossRefGoogle Scholar
  73. 73.
    Bonser RS, Adu D, Franklin I, McMaster P: Cyclosporine-induced helomytic uremic syndrome in liver allograft recipients. Lancet, 2: 1337–1338, 1984.PubMedCrossRefGoogle Scholar
  74. 74.
    Wolfe JA, McCann RL, Sanfilippo F: Cyclosporine-associated microangiopathy in renal transplantation. A severe but potentially reversible form of early graft injury. Transplantation, 41: 541–543, 1986.CrossRefGoogle Scholar
  75. 75.
    Zoja C., Furci L, Ghilardi F, Zilio P, Benigni A, Remuzzi G: Cyclosporin-induced endothelial cell injury. Lab Invest, 55: 455–462, 1986.PubMedGoogle Scholar
  76. 76.
    Myers BD, Ross J, Newton L, Luetscher J, Perlroth M: Cyclosporine-associated chronic nephropathy. N Eng J Med, 311: 699–705, 1984.CrossRefGoogle Scholar
  77. 77.
    Palestine AG, Nussenblatt RB, Chan C-C: Side effects of systemic cyclosporine in patients not undergoing transplantation. Am J Med, 77: 652–656, 1984.PubMedCrossRefGoogle Scholar
  78. 78.
    Svenson K, Bohman S-0, Hallgren R: Renal interstitial fibrosis and vascular changes. Occurrence in patients with autoimmune diseases treated with cyclosporine. Arch Intern Med, 146: 2007–2010, 1986.PubMedCrossRefGoogle Scholar
  79. 79.
    Stanek B, Kovarik J, Rasoul-Rockenschaub S, Silberbauer K: Renin-angiotensin-aldosterone system and vasopressin in in cyclosporine-treated renal allograft recipients. Clin Nephrol, 28: 186–189, 1987.PubMedGoogle Scholar
  80. 80.
    Pfeilschifter J, Ruegg UT: Cyclosporin A augments angiotensin II-stimulated rise in intracellular free calcium in vascular smooth muscle cells. Biochem J, 248: 883–887, 1987.PubMedGoogle Scholar
  81. 81.
    Myers BD, Sibley R, Newton L, Tomlanovich SJ, Boshkos C., Stinson E, Luetscher JA, Whitney DJ, Krasny D, Coplon NS, Perlroth MG: The long-term course of cyclosporine-associated chronic nephropathy. Kidney Int, 33: 590–600, 1988.PubMedCrossRefGoogle Scholar
  82. 82.
    Bantle JP, Nath KA, Sutherland DER, Najarian JS, Ferris TF: Effects of cyclosporine on the renin-angiotensin-aldosterone system and potassium excretion in renal transplant recipients. Arch Intern Med, 145: 505–508, 1985PubMedCrossRefGoogle Scholar
  83. 83.
    Foley RJ, Hammer RW, Weinman EJ: Serum potassium concentration in cyclosporine- and azathioprine-treated renal transplant patients. Nephron, 40: 280–285, 1985.PubMedCrossRefGoogle Scholar
  84. 84.
    Cohen SL, Boner G, Rosenfeld JB, Shmueli D, Sperling O, Yusim A, Todd-Pokropek A, Snapira Z: The mechanism of hyperuricaemia in cyclosporine-treated renal transplant recipients. Transplant Proc, 19: 1829–1830, 1987.PubMedGoogle Scholar
  85. 85.
    Hoyer PF, Lee IkJ, Oemar BS, Krohn HP, Offner G, Brodehl J: Renal handling of uric acid under cyclosporin A treatment. Pediatr Nephrol, 2: 18–21, 1988.PubMedCrossRefGoogle Scholar
  86. 86.
    Barton CH, Vaziri NS, Martin DC, Choi S, Alikhani S: Hypomagnesemia and renal magnesium wasting in renal transplant recipients receiving cyclosporine. Am J Med, 83: 693–699, 1987.PubMedCrossRefGoogle Scholar
  87. 87.
    Iaina A, Herzog D, Cohen D, Gavendo S, Kapuler S, Serban I, Schiby G, Eliahou HE: Calcium entry-blockade with verapamil in cyclosporine A plus ischemia induced acute renal failure in rats. Clin Nephrol, 25 (Suppl 1): S168–S170, 1986.PubMedGoogle Scholar
  88. 88.
    Sumpio BE, Baue AE, Chaudry IH: Alleviation of cyclosporine nephrotoxicity with verapamil and ATP-MgCl2: mitochondrial respiratory and calcium studies. Ann Surg, 206: 655–660, 1987.PubMedCrossRefGoogle Scholar
  89. 89.
    Feehally J, Walls J, Mistry N, Horsburgh T, Taylor J, Veitch PS, Bell PRF: Does nifedipine ameliorate cyclosporine A nephrotoxicity? Br Med J, 295: 310–311, 1987.CrossRefGoogle Scholar
  90. 90.
    Curtis JJ, Luke RG, Dubovsky E, Diethelm Ag, Whelchel JD, Jones P: Cyclosporin in therapeutic doses increases renal allograft vascular resistance. Lancet, 2: 477–478, 1986.PubMedCrossRefGoogle Scholar
  91. 91.
    Wheatley HC, Datzman M, Williams JW, Miles DE, Hatch FE: Long-term effects of cyclosporine on renal function in liver transplant recipients. Transplantation, 43: 641–647, 1987.PubMedCrossRefGoogle Scholar
  92. 92.
    Palestine AG, Austin III HA, Balow JE, Antonovych TT, Sabnis SG, Preuss HG, Nussenblatt RB: Renal histopathologic alterations in patients treated with cyclosporine for uveitis. N Eng J Med, 314: 1293–1298, 1986.CrossRefGoogle Scholar
  93. 93.
    Nahman NS Jr, Cosio FG, Kolkin S, Mendell JR, Sharma HM: Cyclosporine nephrotoxicity without major organ transplantation. Ann Intern Med, 106: 400–401, 1987.PubMedGoogle Scholar
  94. 94.
    Keown PA, Stiller CR, Cameron Wallace A: Nephrotoxicity of cyclosporin A. In: Kidney Transplant Rejection (Eds. GM Williams, JF Burdick and K Solez), Marcel Dekker Inc., New York, 1986, pp 423–457.Google Scholar
  95. 95.
    Miescher PA, Favre H, Chatelanat F, Mihatseh MJ: Combined steroid-cyclospor in treatment of chronic autoimmune diseases. Klin Wochenschr, 65:727–736, 1987.PubMedCrossRefGoogle Scholar
  96. 96.
    Loertscher R: Cyclosporine-associated nephrotoxicity is not intractable. Transplant Proc, 19: 3486–3489, 1987.PubMedGoogle Scholar
  97. 97.
    Morris PJ, French ME, Dunnill MS, Hunnisette AGW, Ting A, Thompson JF, Wood RFM: A control trial of cyclosporine in renal transplantation with conversion to azathioprine and prednisolone after three months. Transplantation, 36: 273–277, 1983.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1989

Authors and Affiliations

  • V. E. Andreucci
    • 1
  • G. Fuiano
    • 1
  1. 1.Department of Nephrology, Second Medical SchoolUniversity of NaplesNaplesItaly

Personalised recommendations